<DOC>
	<DOCNO>NCT00011934</DOCNO>
	<brief_summary>RATIONALE : Biological therapy may increase number immune cell find bone marrow may help person 's immune system recover side effect chemotherapy use treat chronic myeloid leukemia . Bone marrow transplantation may able replace immune cell destroy chemotherapy . PURPOSE : Phase II trial study effectiveness bone marrow transplantation , chemotherapy , biological therapy treat patient chronic myeloid leukemia .</brief_summary>
	<brief_title>Bone Marrow Transplantation Plus Biological Therapy Treating Patients With Chronic Myeloid Leukemia</brief_title>
	<detailed_description>OBJECTIVES : I . Determine one year event-free survival patient chronic phase chronic myeloid leukemia receive sargramostim ( GM-CSF ) -treated autologous bone marrow transplantation follow GM-CSF interferon alfa . II . Determine toxicity regimen patient . OUTLINE : Patients undergo harvest autologous bone marrow . A portion cell treat ex vivo sargramostim ( GM-CSF ) 3 day . Patients receive myeloablative chemotherapy busulfan cyclophosphamide day -9 -2 accord preparative regimen protocol . Patients undergo sargramostim ( GM-CSF ) -treated autologous bone marrow transplantation day 0 . Patients receive GM-CSF subcutaneously daily day 5-180 , interferon alfa daily day 90-180 . Patients follow monthly 1 year , every 6 month 2 year , annually 3 year . PROJECTED ACCRUAL : A total 9-19 patient accrue study within 2-3 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis chronic phase chronic myeloid leukemia ( CML ) cytogenetic and/or molecular analyse No 10 % blast blood bone marrow morphology Philadelphia ( Ph ) chromosome positive Ph chromosomenegative CML allow evidence BCRABL rearrangement molecular FISH analysis evidence P120 protein Duration CML le 3 year , unless cytogenetic remission interferon achieve Failed obtain maintain complete cytogenetic remission prior trial interferon therapy Absence detectable PHnegative cell bone marrow blood 6 month therapy Lack progressive increase Phnegative cell 6 12 month therapy Less 50 % Phnegative cell 12 month therapy Absence complete cytogenetic remission 24 month therapy Inability tolerate prior interferon therapy No accelerate phase blast crisis CML , chronic myelomonocytic leukemia , juvenile CML Concurrent enrollment busulfan cyclophosphamide preparative regimen protocol PATIENT CHARACTERISTICS : Age : 12 70 Performance status : Not specify Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Not specify Renal : Not specify Other : No history intolerance sargramostim ( GMCSF ) PRIOR CONCURRENT THERAPY : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>Philadelphia chromosome positive chronic myelogenous leukemia</keyword>
	<keyword>Philadelphia chromosome negative chronic myelogenous leukemia</keyword>
</DOC>